<DOC>
	<DOCNO>NCT02419820</DOCNO>
	<brief_summary>Randomized , Double-blind , Placebo-controlled , Dose-escalation , Repeated Single Oral Dosing Phase I Study Assess Pharmacokinetics , Pharmacodynamics Safety APD791 ( Temanogrel ) Co-administered Aspirin Clopidogrel .</brief_summary>
	<brief_title>Dose-escalation , Repeated Single Oral Dosing Study</brief_title>
	<detailed_description>1 . To investigate pharmacokinetic pharmacodynamic characteristic Temanogrel orally co-administered Aspirin and/or Clopidogrel healthy subject . person determine suitable purpose clinical trial investigator consideration age health status volunteer select 2 . Assess safety Temanogrel orally co-administered Aspirin and/or Clopidogrel healthy subject .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>APD791</mesh_term>
	<criteria>1. healthy adult 20 45 year old time visit screen 2. person able give write consent 3. person 50 85 kg time visit screen 4. woman negative serum hCG test time visit day trial , nursing , woman agree double contraception , medically approve , time visit screen 90 day last administration clinical trial drug , contraceptive operation later 120 day visit screening , menopausal , man contraceptive operation later 120 day visit screening , agree double contraception , medically approve , time visit screen 90 day last administration clinical trial drug , also agree donate sperm 5. person hemoglobin 12 g/dL time screening ( woman hemoglobin 11 g/dL ) 6. person whose vital sign normal range time visit screening , medically determine clinically significant investigator 1. person medical history gastric ulcer , duodenal ulcer esophageal ulcer within 90 day time visit screen 2. person medical history gastrointestinal disease ( e.g . Crohn 's disease , ulcerative colitis , etc . ) surgery ( exclude uncomplicated appendectomy herniotomy ) affect absorption clinical trial drug 3. person medical history blood coagulation disorder hemorrhagic disease , clinically significant abnormal finding decide investigator blood coagulation test time screen 4. woman medical history dysfunctional uterine bleeding within year time visit screen 5. person medical history epilepsy convulsion 6. person medical history internal organ transplant 7. person expect hard complete clinical trial surgery medical procedure plan within clinical trial period 8. person medical history clinically significant new disease within 30 day time visit screen accord investigator 's decision 9. person hypersensitivity reaction drug gelatin , medical history clinically significant hypersensitivity reaction 10. person history drug abuse , positive reaction drug possible abused urine drug screen 11. person medical history alcohol abuse within two year time visit screen 12. person smoker , positive reaction urine nicotine test conduct time visit screen 13. person donate whole blood within 60 day constituent blood within 30 day , receive blood transfusion within 30 day time visit screen 14. person take clinical trial drug within 90 day time visit screen 15. person take prescription drug within 30 day , contraindicate drug oriental medicine within 14 day time visit screen 16. person positive reaction serum test ( hepatitis B test , hepatitis C test , HIV test , syphilis test ) 17. person hepatic enzyme ( AST , ALT ) 2.5 time reference upper limit ( UNL ) total bilirubin 1.5 time reference upper limit ( UNL ) creatinine 1.25 time reference upper limit ( UNL ) 18. person expect hard complete clinical trial due physical mental status accord investigator 's medical decision time visit screen</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>